Mounjaro questions people ask: uses, cost, doses, and more

Mounjaro is the brand name for tirzepatide, a once-weekly injection made by Eli Lilly and sold in the US under New Drug Application 215866 ^[1][2]. The FDA first approved it on May 13, 2022, for adults with type 2 diabetes ^[2][6]. Since then the label has grown: it now covers children as young as 10 with type 2 diabetes, and it includes an indication to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk ^[1][3].

This page answers the questions people ask most often about Mounjaro: what it treats, how it compares with Zepbound and with semaglutide products, what the heart trial actually showed, which doses exist, what it costs with and without insurance, its side effects, and where compounded tirzepatide stands legally. Every figure comes from the FDA label, FDA records, the drugmaker’s pricing pages, the trial publications, or court and agency documents cited below.

What is Mounjaro and who makes it?

Mounjaro is a single molecule that activates two receptors: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor ^[1][4]. It is injected under the skin once a week ^[1][4]. Eli Lilly and Company is the maker and the holder of the FDA application ^[1][2].

Mounjaro and Zepbound are the only FDA-approved tirzepatide products on the US market ^[16]. Lilly’s exclusive right to make tirzepatide products extends to 2027, according to the Fifth Circuit court opinion in the compounding case ^[16].

What is Mounjaro used for?

The US label lists two uses. First, as an add-on to diet and exercise to improve blood sugar control in adults and children 10 years and older with type 2 diabetes ^[1][3]. Second, to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events ^[1][2][3].

The pediatric indication for ages 10 and up was approved on December 19, 2025, based on SURPASS-PEDS, a placebo-controlled phase 3 trial in children and adolescents with type 2 diabetes ^[2][5][20]. The cardiovascular indication was approved by FDA action on August 27, 2026, and Lilly announced it on August 28, 2026 ^[1][2][3]. It is not known whether Mounjaro is safe and effective in children under 10 ^[3].

Is Mounjaro the same as Zepbound?

Same drug, different label. Mounjaro and Zepbound both contain tirzepatide and both are made by Eli Lilly ^[4][16]. Zepbound was approved in November 2023 and is indicated for adults with obesity, or overweight with at least one weight-related condition, and for adults with moderate-to-severe obstructive sleep apnea and obesity ^[4][16].

In the US, Mounjaro’s label covers type 2 diabetes and cardiovascular risk, while Zepbound’s covers weight management and sleep apnea ^[1][4]. Outside the US, Mounjaro is approved in some countries for obesity and overweight with weight-related conditions as well ^[4].

How does Mounjaro compare with Ozempic and Wegovy (semaglutide)?

The main head-to-head evidence is SURMOUNT-5, a phase 3b open-label trial of 751 adults with obesity but without type 2 diabetes, published in the New England Journal of Medicine on May 11, 2025, and funded by Eli Lilly ^[7]. Participants received the maximum tolerated dose of tirzepatide (10 mg or 15 mg weekly) or semaglutide (1.7 mg or 2.4 mg weekly) for 72 weeks ^[7].

At week 72, average weight change was -20.2% with tirzepatide versus -13.7% with semaglutide, and waist circumference fell 18.4 cm versus 13.0 cm ^[7]. Gastrointestinal events were the most common side effects in both groups, mostly mild to moderate and occurring mainly during dose escalation ^[7]. The trial was open-label, Lilly-funded, and enrolled people with obesity but without diabetes ^[7].

Does Mounjaro reduce heart attack and stroke risk?

Yes, in one specific population: adults with type 2 diabetes already at high cardiovascular risk. The evidence is SURPASS-CVOT, a trial of 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, randomized 1:1 across 640 sites in 30 countries, with a median follow-up of about four years ^[3][4]. Lilly described it as the first cardiovascular outcomes trial comparing two incretin medicines head-to-head rather than against a placebo ^[3].

The comparator was dulaglutide (Trulicity) 1.5 mg, another diabetes injection with established cardiovascular benefit ^[3][4]. Mounjaro’s rate of cardiovascular death, non-fatal heart attack, or non-fatal stroke (MACE-3) was 8% lower than dulaglutide’s, with a hazard ratio of 0.92 (95.3% CI 0.83 to 1.01; p = 0.086), which met the prespecified bar for non-inferiority ^[3][4]. All-cause death was 16% lower with tirzepatide (hazard ratio 0.84), but that result was not controlled for multiplicity ^[4]. During the trial, 13.3% of tirzepatide participants stopped treatment due to adverse events, versus 10.2% on dulaglutide ^[4].

What doses does Mounjaro come in?

The label states a starting dosage of 2.5 mg injected once weekly, with increases in 2.5 mg increments after at least 4 weeks on a dose if more blood sugar control is needed ^[1]. The label’s maximum is 15 mg weekly for adults and 10 mg weekly for pediatric patients 10 and older ^[1]. Dosing decisions belong with a prescriber; this page only describes what the label states.

Mounjaro comes in several forms ^[1][2]:

Form	Strengths
Single-dose pen or single-dose vial	2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL
Multi-dose vial or single-patient-use KwikPen	10, 20, 30, 40, 50, or 60 mg per 2.4 mL — each holds four fixed doses

The KwikPen presentations were approved on January 20, 2026, and the label says never to share a KwikPen between patients, even with a new needle ^[1][8]. The label also says Mounjaro can be injected at any time of day, with or without meals, in the abdomen, the thigh, or the back of the upper arm when another person gives the injection, rotating sites with each dose ^[1].

How much does Mounjaro cost without insurance?

The list price — the wholesale acquisition cost (WAC) at which Lilly sells to wholesalers — is $1,112.16 per fill, where one fill is a month’s supply of four pens ^[9]. That figure, accessed January 1, 2026, is a list price; pharmacy prices depend on insurance, pharmacy charges, and any discounts ^[9].

For people paying cash, LillyDirect offers the single-dose pen for self-pay starting at $499 per month across all six strengths, with a prescription required and taxes and fees possibly extra ^[10]. LillyDirect fills prescriptions through four dispensing pharmacies: Amazon Pharmacy, Fuze Health, Gifthealth, and Walmart Pharmacy ^[10]. Separately, the TrumpRx website lists Zepbound at $299 per month; TrumpRx does not sell drugs directly ^[11][13].

What does the Mounjaro savings card pay for?

The Mounjaro Savings Card is for commercially insured patients only ^[12]. Its terms ^[12]:

Your situation	You pay	Card savings cap
Commercial plan covers Mounjaro	As little as $25 per 1-, 2-, or 3-month fill	Up to $150 per 1-month fill, $450 per 3-month fill, $1,950 per calendar year
Commercial plan does not cover Mounjaro	As low as $499 per month	Up to $647 per month, $8,411 per year

To be eligible you need commercial drug insurance, a prescription for an FDA-approved use, US or Puerto Rico residency, and age 18 or older ^[12]. People with Medicaid, Medicare, Medicare Advantage, Medigap, DoD, VA, or TRICARE coverage are excluded ^[9][12]. The card works for a maximum of 13 fills per calendar year and expires December 31, 2026 ^[12].

Is Mounjaro covered by Medicare or Medicaid?

The Medicare GLP-1 Bridge program, which started July 1, 2026, covers Foundayo, Wegovy, and the Zepbound KwikPen only, with a $50 monthly copayment ^[13]. People with type 2 diabetes are not Bridge-eligible; their Medicare Part D plan might cover GLP-1 drugs for that condition ^[13].

Medicare patients can also use the Medicare Prescription Payment Plan (M3P), a free budgeting tool that spreads prescription costs into fixed monthly payments across the plan year ^[12]. For Medicaid, eligibility and copayments vary state by state; Lilly’s pricing page points to the state overviews at medicaid.gov ^[9].

What are Mounjaro’s side effects and warnings?

The most common adverse reactions, reported in at least 5% of patients, are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain ^[1].

Mounjaro carries a boxed warning: tirzepatide causes thyroid C-cell tumors in rats, and it is not known whether it causes such tumors, including medullary thyroid carcinoma, in humans ^[1]. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1].

Other label warnings include pancreatitis; hypoglycemia when used with insulin or a sulfonylurea; serious hypersensitivity reactions; acute kidney injury from dehydration; severe gastrointestinal reactions; diabetic retinopathy complications; gallbladder disease; and pulmonary aspiration during general anesthesia or deep sedation ^[1]. Alopecia (hair loss) was added to the postmarketing experience section of the label on May 28, 2025 ^[14][1]. The label also advises people using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase, and notes that based on animal studies the drug may cause fetal harm ^[1].

How much weight do people with type 2 diabetes lose on Mounjaro?

Mounjaro’s US label indications cover blood sugar control and cardiovascular risk reduction; the weight management indication belongs to Zepbound, which contains the same active ingredient ^[1][4]. Trials in people with type 2 diabetes have measured weight, though. In SURPASS-CVOT, at 36 months, body weight fell 12.06% with tirzepatide versus 4.95% with dulaglutide, from a mean baseline of 92.6 kg, and HbA1c fell 1.73% versus 0.90% from a baseline of 8.39% ^[4].

The widely cited -20.2% figure comes from SURMOUNT-5, which enrolled people with obesity but without diabetes ^[7].

Is compounded tirzepatide legal?

Generally not anymore. FDA placed Mounjaro on its drug shortage list in December 2022, which temporarily allowed compounders to make copies; the FDA declared the shortage resolved on October 2, 2024, and confirmed that decision on December 19, 2024 ^[16]. Once the shortage ended, compounding tirzepatide copies became unlawful again ^[16].

FDA’s enforcement discretion wound down after a March 5, 2025 district court ruling: it ended for state-licensed pharmacies (503A compounders) after that ruling, and for outsourcing facilities (503B) on March 19, 2025 ^[15]. On August 27, 2026, the Fifth Circuit Court of Appeals affirmed FDA’s position in the case, No. 25-10600 ^[16]. In addition, on April 30, 2026, FDA proposed excluding tirzepatide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it, with comments due by June 29, 2026 ^[17]. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before reaching patients ^[16][18].

What about the impurity found in compounded tirzepatide with vitamin B12?

In a public letter dated March 12, 2026, Lilly reported that its own testing found an impurity from a chemical reaction between tirzepatide and vitamin B12 in all 10 samples of compounded products it tested ^[18]. Lilly notified the FDA and called for a nationwide recall of products combining the two ingredients ^[18].

This is Lilly’s testing, not an FDA finding. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Lilly had not disclosed enough about its sampling process to fully assess any health risk to consumers ^[18].

Is there a Mounjaro pill or a generic?

Mounjaro is an injection. The pill people ask about is Foundayo (orforglipron), a once-daily GLP-1 pill from Lilly approved on April 1, 2026 for weight management in adults — a different molecule from tirzepatide ^[19]. Foundayo self-pay starts at $149 per month for the lowest dose ^[19].

As for a generic: Lilly’s exclusivity extends to 2027 per the Fifth Circuit opinion, and Mounjaro and Zepbound are the only FDA-approved tirzepatide products ^[16].

Sources

1. National Library of Medicine DailyMed. MOUNJARO (tirzepatide) injection, solution.
2. US Food and Drug Administration. Drugs@FDA: New Drug Application 215866, Mounjaro (tirzepatide).
3. Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. August 28, 2026.
4. Eli Lilly and Company. Lilly’s Mounjaro (tirzepatide) demonstrated cardiovascular protection in landmark head-to-head trial. July 31, 2025.
5. US Food and Drug Administration. Supplement approval letter, NDA 215866/S-039, Mounjaro (tirzepatide) injection. 2025.
6. US Food and Drug Administration. NDA approval letter, NDA 215866, Mounjaro (tirzepatide) injection. 2022.
7. New England Journal of Medicine. Tirzepatide as compared with semaglutide for the treatment of obesity.
8. US Food and Drug Administration. Supplement approval letter, NDA 215866/S-009, Mounjaro KwikPen (tirzepatide) injection. 2026.
9. Eli Lilly and Company. Mounjaro cost information, with or without insurance.
10. Eli Lilly and Company. Authentic Mounjaro (tirzepatide) shipped to you, LillyDirect.
11. TrumpRx. TrumpRx: the price. Home page.
12. Eli Lilly and Company. Savings and coverage, Mounjaro (tirzepatide).
13. Medicare.gov. Weight loss drugs.
14. US Food and Drug Administration. Supplement approval letter, NDA 215866/S-031, Mounjaro (tirzepatide) injection. 2025.
15. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
16. US Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA, No. 25-10600. August 27, 2026.
17. US Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list.
18. Reuters. Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks. March 12, 2026.
19. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss. April 1, 2026.
20. PubMed. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.